Cigna (NYSE: CI) Tops Q3 Profit Expectations Fueled by Robust Pharmacy Benefits Segment

Cigna (NYSE: CI) reported better-than-expected earnings for the third quarter, largely driven by standout results in its health services division, Evernorth. This unit, which includes the pharmacy benefit manager Express Scripts, has become a crucial profit engine amid a challenging insurance environment.

The company posted an adjusted profit of $7.83 per share, edging past Wall Street's consensus estimate of $7.65. Notably, Evernorth's revenue jumped about 15% to $60.39 billion, supported by growing client numbers and solid sales in Accredo, its specialty pharmacy focusing on costly medications.

Unlike many of its peers facing headwinds from government-backed insurance plans with soaring costs, Cigna has managed to buffer the impact thanks to its greater reliance on employer-sponsored plans and pharmacy benefit management services. Express Scripts' role in negotiating drug prices gives Cigna a competitive edge in controlling expenses in uncertain healthcare markets.

However, Cigna's medical care ratio-the percentage of premiums spent on medical claims-climbed to 84.8%, higher than the 82.8% registered in the previous year and above analyst estimates of 84.17%. This uptick is partly due to higher claims in the stop-loss insurance segment, which covers employers against catastrophic medical costs. The company reiterated that these increased stop-loss expenses align with its earlier forecasts.

Some investors were holding their breath given prior concerns about stop-loss exposure, but analysts, such as Mizuho's Ann Hynes, viewed the quarter positively, emphasizing that the feared pitfalls in Cigna's stop-loss business have so far been manageable.

Looking ahead, the insurer reaffirmed its full-year adjusted profit forecast at a minimum of $29.60 per share, just slightly below the $29.63 average analyst estimate. This suggests confidence in maintaining momentum despite healthcare sector uncertainties. Cigna plans to phase out prescription drug rebates in certain health plans by 2027, a move likely to reshape its pharmacy benefits approach.

Pre-market trading reflected optimism as shares edged up roughly 2%, settling near $305.20. Given Evernorth's significant contribution and Cigna's strategic positioning, the quarter delivered some relief following a period of cost pressures in the sector.

It remains to be seen how Cigna will navigate the evolving healthcare policies and pricing dynamics heading into 2026. Meanwhile, investors digest the numbers and comments from management's upcoming earnings call for clues about the year ahead.